Vor Bio is licensing global rights to a fusion protein that inhibits two targets to potentially treat the neuromuscular disorder generalized myasthenia gravis. It’s a pivot for Vor, which last ...

About IBI363 (First-in-class PD-1/IL-2α-bias bispecific antibody fusion protein) IBI363 is a first-in-class PD-1/IL-2α-bias bispecific antibody fusion protein independently developed by Innovent ...

2025 ASCO Oral Presentation: Innovent Biologics Announces Updated Data of IBI363 (First-in-class PD-1/IL-2α-bias Bispecific Antibody Fusion Protein) from the Phase 1 PoC Clinical Study in ...

The poster, “Multiplexed spatial profiling of protein and glycan expression using CFP fluor cleavable TSA fluorophores,” was authored by scientists at Spatomics and Vector Laboratories.

A team recently detailed an auto-expression medium to maximize protein production that uses galactose rather than lactose to induce auto-expression.

TFE3 fusion proteins bind the promoters of oxidative metabolism and ferroptosis resistance genes and promote their expression in tRCC.

Learn how analytical methodologies can be used to identify RSV pre- and post-fusion proteins for vaccine development.

On December 4, 2024, the U.S. Food and Drug Administration granted accelerated approval to zenocutuzumab (Bizengri®), the first approved systemic therapy for patients with advanced, unresectable, or ...

To produce recombinant proteins, the expression vector was transfected into DG44-CHO cells (Dhfr negative, CRL-9096, ATCC, Manassas, VA, U.S.A.), and a stable DG44-CHO cell clone was established.

Researchers from Anaveon AG and affiliated organizations presented the discovery and preclinical characterization of ANV-700, a novel proximity-activated cytokine (PAC) compound designed to ...

The FDA has granted a fast track designation to IBI363 for the treatment of unresectable locally advanced or metastatic melanoma that has progressed following at least 1 line of systemic therapy, ...